Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00578071 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Study of Panitumumab, Capecitabine and Oxaliplatin w EBRT for Esophageal Cancer
A Phase 1 study of Cancer of the Esophagus, sponsored by Brian Czito.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT00578071: Completed Phase 1 study of Cancer of the Esophagus, sponsored by Brian Czito.
NCT00578071 is a Phase 1 study of Cancer of the Esophagus that has completed, run by Brian Czito. The registered enrollment target is 29 participants, below the 345-participant average among 3 other Cancer of the Esophagus trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00578071, a Phase 1 study of Cancer of the Esophagus, has completed, sponsored by Brian Czito.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of this trial is to define the maximum tolerated and/or recommended phase II dose of the combination of panitumumab, oxaliplatin and capecitabine in patients undergoing radiation therapy for carcinoma of the thoracic esophagus or gastroesophageal junction. An additional primary objective is to describe the frequency and nature of grade III/IV and grade I/II toxicities associated with this regimen. Secondary objectives include describing 1-year disease-free survival and overall survival rates as well as to estimate clinical and pathologic complete response rates associated with this regimen.
Conditions Studied
Interventions
- DRUG Capecitabine
- DRUG Oxaliplatin
- RADIATION Radiation Therapy (RT)
- DRUG Panitumumab
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2007-12 |
| Est. Completion | 2012-06 |
| Phase | Phase 1 |
What the finished NCT00578071 record still lists
NCT00578071 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 345-participant average among 3 other Cancer of the Esophagus trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Cancer of the Esophagus appearing as the primary indexed condition, and to 4 interventions - of which Capecitabine is the first listed.
NCT00578071 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT00578071 about?
NCT00578071 is a clinical study titled "Phase I/II Study of Panitumumab, Capecitabine and Oxaliplatin w EBRT for Esophageal Cancer". The primary purpose of this trial is to define the maximum tolerated and/or recommended phase II dose of the combination of panitumumab, oxaliplatin and capecitabine in patients undergoing radiation therapy for carcinoma of the thoracic esophagus or gastroesophageal junction. An additional primary o...
What is the current status of trial NCT00578071?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2007-12. Estimated completion is 2012-06.
What conditions does trial NCT00578071 study?
This clinical trial studies the following conditions: Cancer of the Esophagus.
What interventions are being tested in trial NCT00578071?
The interventions under investigation include: Capecitabine (DRUG), Oxaliplatin (DRUG), Radiation Therapy (RT) (RADIATION), Panitumumab (DRUG).
Who is sponsoring clinical trial NCT00578071?
This trial is sponsored by Brian Czito, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00578071 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer of the Esophagus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Mayo Clinic Upper Digestive Disease Survey
RECRUITING
-
Proton Beam Therapy in the Treatment of Esophageal Cancer
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia